Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top

21-06-2023 | Chronic Lymphocytic Leukemia | Congress News | News

EHA 2023

Baseline protein profiles can predict MRD status in CLL

Login to get access

MedNet.nl: The HOVON 141/VISION study shows that protein profiles at baseline in patients with chronic lymphocytic leukemia (CLL) are predictive of minimal residual disease (MRD) status after 15 months of treatment with venetoclax plus ibrutinib.

Related topics

EHA 2023 rotated-square
Targeted Therapy rotated-square
Hematologic Cancer rotated-square
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits